Genetically Engineered Hematopoietic Stem Cells Deliver TGF‐β Inhibitor to Enhance Bone Metastases Immunotherapy

Owing to the immune microenvironment of bones and low selectivity of the drug, patients with bone metastases often respond poorly to immunotherapy. In this study, programmed cell death protein 1 (PD1)‐expressing hematopoietic stem cells (HSCs) are genetically engineered for bone‐targeted delivery of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Beilei, Bai, Jinyu, Tian, Bo, Chen, Hao, Yang, Qianyu, Chen, Yitong, Xu, Jialu, Zhang, Yue, Dai, Huaxing, Ma, Qingle, Fei, Ziying, Wang, Heng, Xu, Fang, Zhou, Xiaozhong, Wang, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534984/
https://www.ncbi.nlm.nih.gov/pubmed/35948516
http://dx.doi.org/10.1002/advs.202201451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534984/
https://www.ncbi.nlm.nih.gov/pubmed/35948516
http://dx.doi.org/10.1002/advs.202201451

Ejemplares similares